BESTOW: A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION

Registry ID

AT-1501-K207

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ELEDON PHARMACEUTICALS, INC.

Start date

2024-06-07

Last update

2023-03-29

Conditions

• KIDNEY TRANSPLANTATION

Related clinical trials

• A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN RECIPIENTS OF KIDNEY TRANSPLANTS WITH LATE ISOLATED MICROVASCULAR INFLAMMATION (MVI) - (TRANSPIRE0
• A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT RECIPIENTS (¿18 YEARS OF AGE)
• SEMAGLUTIDE FOR THE PREVENTION OF POST-TRANSPLANT DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB ADMINISTERED INTRAVENOUSLY IN ADULT PARTICIPANTS AT HIGH RISK OF DELAYED GRAFT FUNCTION AFTER KIDNEY TRANSPLANTATION
• EVALUATION OF THIOSULFATE IN END STAGE RENAL DISEASE AND KIDNEY TRANSPLANTATION
• A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE) RECEIVING 1 DOSE

View on source registry